treatment

Treatment with Uplizna (inebilizumab-cdon) was associated with fewer attacks and reduced disability in Chinese adults with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) antibodies, a real-world study found. The estimated one-year attack-free rate was 95.5%. According to the researchers, the findings “provided evidence on the real-world…

MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo at preventing relapses and controlling disease activity in people with the autoimmune disease. That’s according to data from the Phase 3 portion of a China-based Phase 1b/3 clinical trial…

Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab), two approved treatments for neuromyelitis optica spectrum disorder (NMOSD), may work better than rituximab — a drug not cleared for treating the autoimmune disease but often used off-label — for preventing NMOSD relapses, according to a new review. Still, the study findings…

A short-course of Soliris (eculizumab) treatment during relapses may help people with neuromyelitis optica spectrum disorder (NMOSD) recover faster when standard therapies fail, a small study in China suggests. Patients who saw little or no improvement after corticosteroids, with or without plasma exchange, experienced meaningful gains in mobility…

Ever since neuromyelitis optica spectrum disorder (NMOSD) introduced pain into my life, I’ve been trying to exorcise it from my body. I’ve become a formidable opponent to pain, but parts of it still frighten me. The spasms were the worst. They once felt like someone was pouring boiling water…

MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep most NMOSD patients free of relapses for up to two years, while being generally safe and well tolerated. That’s according to data from the Phase 1b portion of a single-center…

Use of the approved therapy Uplizna (inebilizumab) reduces the risk of relapse and worsening disability in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether patients had previously received conventional immunosuppressive treatments. These are the findings of a post-hoc analysis of data from the Phase 2/3…

Ultomiris (ravulizumab-cwvz) was associated with sustained disease control in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether they had been previously treated off-label with rituximab. That’s according to a new analysis of data from the Phase 3 CHAMPION-NMOSD clinical trial (NCT04201262), whose results supported…

Infusions of stem cells derived from umbilical cords proved safe for people with neuromyelitis optica spectrum disorder (NMOSD) and look to be a promising new therapy for the autoimmune disease, according to data from an early clinical trial conducted in China. In the trial, the two-year treatment, which consisted…

Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with neuromyelitis optica spectrum disorder (NMOSD) in Japan. That’s according to a new study that tracked outcomes from Japanese NMOSD patients given the approved injection therapy in real-world practice. “Overall, most…